Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gabapentin + ropivacaine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Local Injection, Infusion
01
Overview
A combination therapy consisting of gabapentin, an anticonvulsant medication, and ropivacaine, a local anesthetic. This combination is used primarily for pain management, particularly for neuropathic pain conditions such as trigeminal neuralgia and post-surgical pain. The combination provides superior pain control compared to either agent alone, with reduced gabapentin dosage requirements and fewer side effects.
02
Targets
CACNA2D2 (α2δ-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on gabapentin + ropivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gabapentin + ropivacaine.